SynAct Pharma AB (FRA:8F8)

Germany flag Germany · Delayed Price · Currency is EUR
1.814
+0.012 (0.67%)
At close: Dec 4, 2025
72.93%
Market Cap 99.40M
Revenue (ttm) n/a
Net Income (ttm) -9.61M
Shares Out n/a
EPS (ttm) -0.20
PE Ratio n/a
Forward PE 75.99
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 1.770
Previous Close 1.802
Day's Range 1.770 - 1.820
52-Week Range 0.743 - 2.320
Beta n/a
RSI 43.73
Earnings Date Feb 18, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 6
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 8F8
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

There is no news available yet.